Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04702243 · ClinicalTrials.gov registry record
Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults
A clinical trial, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 436
- Enrollment target
NCT04702243: Completed study, sponsored by University of North Carolina, Chapel Hill.
NCT04702243 is a clinical trial that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 436 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04702243 has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 436 participants
- Enrollment target
Study Summary
The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).
Primary Outcome
A commercial genetic panel will be used to test for disease causing mutation in PCD or PID. If the commercial panel does not yield positive results, WES research testing will be used to identify disease causing mutations in PCD and PID in order to confirm the diagnosis.
Interventions
- DIAGNOSTIC_TEST Genetic Testing for PCD or PID
- OTHER Unaffected Family Member Genetic Testing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 436 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2025-08-06 |
What the finished NCT04702243 record still lists
NCT04702243 is an observational study that tracks outcomes without assigning an intervention. The registered 436 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Genetic Testing for PCD or PID is the first listed.
NCT04702243 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04702243 about?
NCT04702243 is a clinical study titled "Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults". The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).
What is the current status of trial NCT04702243?
This trial is currently completed. The enrollment target is 436 participants. The study started on 2020-12-01. Estimated completion is 2025-08-06.
What interventions are being tested in trial NCT04702243?
The interventions under investigation include: Genetic Testing for PCD or PID (DIAGNOSTIC_TEST), Unaffected Family Member Genetic Testing (OTHER).
Who is sponsoring clinical trial NCT04702243?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02622542 · 436 participants · NA
ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy
- NCT05918211 · 436 participants · Phase 3
Fontan Udenafil Exercise Longitudinal Assessment Trial - 2
- NCT06966479 · 436 participants · Phase 2
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
- NCT07318493 · 436 participants · NA
Antiseptic-Coated Sutures and Pancreatic Fistula Risk After Pancreatoduodenectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI